Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 4, 2025
Reporting Period: Second quarter ended June 30, 2025
This filing announces the financial results for the second quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document for the results and does not contain specific numerical data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release (Exhibit 99.1) for these figures.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. Specific comparisons are expected to be detailed in the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release containing management commentary, but the text of the commentary is not included in this document.
Legal Disclaimer: The information in this Form 8-K, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. It shall not be deemed incorporated by reference in any other filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for updated full-year 2025 guidance or outlook statements in the press release.
- Confirm any new risks or contingencies disclosed in the full press release text.